Trial Profile
An Open-Label, Single-Arm, Multicenter Pilot Study to Evaluate Safety, Tolerability, and Efficacy of ALN-PCSSC in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Inclisiran (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Therapeutic Use
- Acronyms ORION-2
- Sponsors The Medicines Company
- 27 May 2019 According to The Medicines Company media release, data from the study were presented at the 87th European Atherosclerosis Society (EAS) Congress 2019.
- 27 May 2019 Results presented in The Medicines Company media release.
- 25 Apr 2019 According to the Medicines Company, data from this trial will be presented during a late-breaking abstract session at the 87th European Atherosclerosis Society Congress on May 27, 2019.